33
total announcements
544210.BO · 15 min delayed
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced an earnings call for Q2 FY27 results, scheduled for November 3, 2026, to discuss unaudited financial results and performance for the quarter and half-year ended September 30, 2026.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 03/11/2026 to consider and approve Unaudited Financial Results for the quarter and half-year ended September 30, 2026.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has confirmed under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, that no securities were received for dematerialization during the quarter ended September 30, 2026.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has approved a scheme of amalgamation of its wholly owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, with the holding company, subject to regulatory approvals.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has received orders from the Income-tax Department imposing an aggregate penalty of Rs. 57,73,96,732 for Financial Year 2014-15 to Financial Year 2020-21. The company is evaluating legal remedies, including filing an appeal.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the closure of its trading window for insiders from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending September 30, 2026.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced its Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation highlights the company's growth, revenue, and earnings, with a 17.6% CAGR over FY24-FY26 and a 33.6% earnings CAGR.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced changes to its Board of Directors, including the retirement of Mr. Berjis Desai, re-appointment of Dr. Mukund Gurjar and Mr. Satish Mehta, and appointment of Mr. Raghu Kumar as an Independent Director.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the voting results of its 45th Annual General Meeting (AGM), which was held on September 21, 2026, through video conference. All the items of business as set out in the Notice of the 45th AGM have been duly approved by the members with requisite majority.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has dispatched a letter to members whose email addresses are not registered with the company or depository participants, providing a web-link to the Annual Report 2025-26 and Notice of 45th Annual General Meeting.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced a schedule for an investor meet on September 04, 2026, with a group of institutional investors in Pune. The meeting is subject to change due to exigencies and no unpublished price-sensitive information will be shared.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has reaffirmed its credit ratings by CARE Ratings Limited, citing the company's healthy business risk profile, diversified revenue base, leadership position, and well-established R&D capabilities.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has published a newspaper advertisement for its 45th Annual General Meeting (AGM) and e-voting information, to be held on September 21, 2026, through video conferencing or other audio-visual means.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has released its Business Responsibility and Sustainability Report for the Financial Year 2025-26, highlighting its commitment to responsible business practices, sustainable growth, and creating long-term value for stakeholders.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the notice of its 45th Annual General Meeting (AGM) to be held on September 21, 2026, through video conferencing. The AGM will consider the annual report for the financial year 2025-26 and other business.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced its Annual Report for the Financial Year 2025-26, including the Notice of the 45th Annual General Meeting, scheduled to be held on September 21, 2026.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has allotted 19,100 equity shares to eligible employees under the Emcure - Employee Stock Option Scheme 2013, increasing the issued and paid-up share capital to Rs.1,89,69,92,470.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd announced the transcript of their Q1 FY27 earnings call, with the CEO Satish Mehta discussing the company's performance and organizational updates, including the appointment of a new Chairman and the promotion of Samit Mehta as Chief Operating Officer.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has received the Establishment Inspection Report (EIR) from the USFDA, with the inspection status classified as Voluntary Action Indicated (VAI) and the inspection standing closed.
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd has announced the schedule of participation in Investor Conferences by its officials, including Emkay 'Confluence 2026', Motilal Oswal 22nd Annual Global Investor Conference, Elara India Dialogue 2026, Kotak Healthcare Forum 2026, and 11th Annual J.P. Morgan India Conference.